We represented a Fortune 500 company in the life sciences industry in an investigation by the U.S. Department of Justice and Securities and Exchange Commission of alleged FCPA and local law violations relating to the company’s operations in Europe and conduct of its distributors. This representation included providing guidance and advice about the pros and cons of self-reporting, the potential value of cooperation, and benefits of remedial actions taken to enhance the existing compliance program.
Investigation of FCPA Violations in Europe
You Also May Be Interested In:
Represented Quest Diagnostics in its acquisition of Mobile Medical Examination Service
Represented Quest Diagnostics in its acquisition of Cleveland HeartLab
Represented Quest Diagnostics in its acquisition of a California clinical lab network